NCT01846871View on ClinicalTrials.gov

Tivozanib for Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2016

Conditions
Glioblastoma
Interventions
DRUG

Tivozanib

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Massachusetts General Hospital

OTHER

NCT01846871 - Tivozanib for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter